Clinical Trial Update: Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotide [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating the radiolabeled somatostatin antagonist 177Lu-satoreotide for recurrent or progressive meningiomas; the study is curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningioma

Drugs mentioned

• 177Lu-satoreotide (177Lu-satoreotide)

Snippet

Sponsor: University Hospital, Basel, Switzerland | Conditions: Meningioma | Phase 1, Phase 2 | Status: RECRUITING